These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 34854322)
1. Antituberculosis, antioxidant and cytotoxicity profiles of quercetin: a systematic and cost-effective Swain SS; Rout SS; Sahoo A; Oyedemi SO; Hussain T Nat Prod Res; 2022 Sep; 36(18):4763-4767. PubMed ID: 34854322 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of indole-functionalized isoniazid conjugates with potent antimycobacterial and antioxidant efficacy. Gavadia R; Rasgania J; Sahu N; Varma-Basil M; Chauhan V; Kumar S; Mor S; Singh D; Jakhar K Future Med Chem; 2024; 16(17):1731-1747. PubMed ID: 39041719 [TBL] [Abstract][Full Text] [Related]
3. Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug-Able Anti-TB Phytochemicals: A Cost-Effective Platform for Natural Product-Based Drug Discovery. Swain SS; Hussain T Chem Biodivers; 2022 Nov; 19(11):e202200267. PubMed ID: 36307750 [TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of Isatin-Tagged Isoniazid Conjugates with Cogent Antituberculosis and Radical Quenching Competence: In-vitro and In-silico Evaluations. Gavadia R; Rasgania J; Sahu N; Varma-Basil M; Chauhan V; Kumar S; Mor S; Singh D; Jakhar K Chem Biodivers; 2024 Oct; 21(10):e202400765. PubMed ID: 39024129 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates. AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955 [TBL] [Abstract][Full Text] [Related]
6. Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting. Pinhata JMW; Brandao AP; Mendes FF; Rabello MCDS; Ferrazoli L; de Oliveira RS Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2551-2561. PubMed ID: 34297229 [TBL] [Abstract][Full Text] [Related]
7. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA. Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146 [TBL] [Abstract][Full Text] [Related]
8. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. Dalla Costa ER; Ribeiro MO; Silva MS; Arnold LS; Rostirolla DC; Cafrune PI; Espinoza RC; Palaci M; Telles MA; Ritacco V; Suffys PN; Lopes ML; Campelo CL; Miranda SS; Kremer K; da Silva PE; Fonseca Lde S; Ho JL; Kritski AL; Rossetti ML BMC Microbiol; 2009 Feb; 9():39. PubMed ID: 19228426 [TBL] [Abstract][Full Text] [Related]
9. Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis. Chen X; Kong F; Wang Q; Li C; Zhang J; Gilbert GL J Clin Microbiol; 2011 Oct; 49(10):3450-7. PubMed ID: 21832014 [TBL] [Abstract][Full Text] [Related]
11. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid. Unissa AN; Doss C GP; Kumar T; Swathi S; Lakshmi AR; Hanna LE J Glob Antimicrob Resist; 2017 Dec; 11():57-67. PubMed ID: 28743650 [TBL] [Abstract][Full Text] [Related]
12. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase. Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857 [TBL] [Abstract][Full Text] [Related]
13. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic. Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa. Pitso L; Potgieter S; Van der Spoel van Dijk A S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590 [TBL] [Abstract][Full Text] [Related]
15. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach. Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808 [TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. Guo H; Seet Q; Denkin S; Parsons L; Zhang Y J Med Microbiol; 2006 Nov; 55(Pt 11):1527-1531. PubMed ID: 17030912 [TBL] [Abstract][Full Text] [Related]
20. [Characterization of the katG, inhA, ahpC, kasA, and oxyR gene mutations in isoniazid-resistant and susceptible strain of Mycobacterium tuberculosis by automated DNA sequencing]. Chen X; Ma Y; Jin Q; Jiang GL; Li CY; Wang Q Zhonghua Jie He He Hu Xi Za Zhi; 2005 Apr; 28(4):250-3. PubMed ID: 15854436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]